Sarepta Therapeutics Inc., a Cambridge company that is developing RNA-based therapeutics, said Friday that Arthur “Art” Krieg, M.D., has been selected as its senior vice president and chief scientific officer.
In this role, Krieg will lead the company’s drug discovery and early-stage research activities. Krieg joins Sarepta from RaNA Therapeutics, where he served as chief executive officer since he co-founded the company in 2011. Previously, he was chief scientific officer of Pfizer’s Oligonucleotide Therapeutics Unit from 2008 to 2011, Sarepta said in a press release.
“We are excited to welcome Art to Sarepta as we advance the field of RNA medicine with our proprietary technologies,” Chris Garabedian, president and chief executive of Sarepta Therapeutics, said in a statement. “With more than two decades of experience in oligonucleotide drug development, Art’s outstanding scientific leadership will support the advancement of our exon skipping franchise in Duchenne muscular dystrophy as well as the expansion of our product pipeline.”
The company’s pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world’s most lethal infectious diseases.